-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on ArriVent BioPharma, Lowers Price Target to $18

Benzinga·10/07/2026 12:59:13
Listen to the news
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $45 to $18.